17 Amendments of Cristian-Silviu BUŞOI related to 2017/2576(RSP)
Amendment 5 #
Citation 7 a (new)
- having regard to the WHO Global Health Sector Strategy on Viral Hepatitis 2016-2021 towards ending viral hepatitis, whose goal is to eliminate it's major public health threat by 2030;
Amendment 6 #
Citation 6 a (new)
- having regard to the European Parliament's Written Declaration on Hepatitis C from 2007;
Amendment 8 #
Citation 9
— having regard to the outcome of the informal EU Health Ministers’ meeting held in Bratislava on 3-4 October 2016 where member States agreed on the support for the development of an integrated EU policy framework on HIV, tuberculosis and Viral Hepatitis C,
Amendment 10 #
Citation 10
— having regard to the Commission Communication of 22 November 2016, entitled “Next steps for a sustainable European future, encompassing the economic, social, environmental dimensions of sustainable development, as well as governance, within the EU and globally”3 , in which the European Commission states it will contribute by monitoring, reporting and reviewing progress towards Sustainable Development Goals in the EU context; _________________ 3 http://ec.europa.eu/europeaid/sites/devco/fi les/communication-next-steps-sustainable- europe-20161122_en.pdf
Amendment 11 #
Citation 11 a (new)
- having regard to the WHO Europe Action Plan for the health sector response to viral hepatitis in the WHO Europe region, whose overall goal is the elimination of viral hepatitis as a public health threat in the European Region by 2030, by reducing morbidity and mortality due to viral hepatitis and its complications, and ensuring equitable access to recommended prevention, testing, care and treatment services for all;
Amendment 19 #
Recital G
Amendment 23 #
Recital G a (new)
G a. whereas the WHO has identified injecting drug use as a major driver of the Hepatitis C epidemic in the European Region, with people who inject drugs (PWID) presenting the majority of new cases;
Amendment 25 #
Recital K a (new)
K a. whereas at the moment there is still an uneven approach at EU level on fighting viral hepatitis, some MS lack in having a national plan, while certain MS have made significant funding commitments and put in place strategies and developed national plans for a comprehensive response to the burden of viral hepatitis;
Amendment 35 #
Paragraph 1
1. Calls on the Commission and the Member States to develop a comprehensive EU Policy Framework addressing HIV/AIDS, Tuberculosis and Viral Hepatitis C, bearing in mind the different situation and specific challenges of EU Member States and their neighbouring countries where the burden of HIV and MDR-TB is highest;
Amendment 38 #
Paragraph 4
4. Calls on the Commission and the Council to play a strong political role in the dialogue with neighbouring countries in Eastern Europe and Central Asia, ensuring that plans for sustainable transition to domestic funding are in place, so that Viral Hepatitis, HIV and TB programmes will be effective, continued and scaled up after the withdrawal of international donors’ support and to continue to work closely with those countries in ensuring they take the responsibility and ownership of Viral Hepatitis, HIV and TB responses;
Amendment 42 #
Paragraph 4 a (new)
4 a. calls on the European Commission to discuss with Member States and future Council Presidencies the possibility of updating the Dublin Declaration to include HIV, Viral Hepatitis and TB on an equal footing;
Amendment 77 #
Paragraph 22
22. Stresses that within the European Union the main route of HCVViral Hepatitis transmission is via injecting drug use as a result of sharing contaminated needles, due to the use of unsterile injecting drug equipment, stresses that hepatitis infection of healthcare workers due to needle stick injuries remains above average; stresses that the provision of harm reduction services, including OST and NSPs, is a critical viral hepatitis prevention strategy, including measures to overcome stigma and discrimination;stresses that anti-HCV and HbsAg tests are frequently not part of reimbursed health check-ups; highlights that more rarely, the virus can be transmitted sexually, or in health and cosmetic care settings due to inadequate infection control practices, or perinatally from an infected mother to the baby;
Amendment 78 #
Paragraph 23
23. Points out that around 30% of people with chronic hepatitis C suffer from liver damage and a small number of those develop cancer, and that Viral Hepatitis C is considered to be one of the leading causes of liver cancer and liver transplants in Europe; points out that the peak of the burden due to viral hepatitis-related complications such as primary liver cancer and transplants is yet to come;
Amendment 83 #
Paragraph 24
24. Emphasizes that the HCV infection can be cured, especially if it is detected and treated with the appropriate antiviral drug combinations, in particular points out that antiviral treatment can now cure over 90% of persons with HCV infection; emphasizes that viral HBV is preventable through vaccine and can be controlled; however less than 50% of people with chronic viral hepatitis are only diagnosed after decades following their infection;;
Amendment 86 #
Paragraph 24 a (new)
24 a. calls on the European Commission, Council and Member States to put in place an EU-wide harmonsied infection surveillance programmes that can detect outbreaks of Viral Hepatitis, TB and HIV in a timely manner, assess trends in incidence, inform disease burden estimates and effectively track in "real time" the diagnosis, treatment and care cascade, including in specific vulnerable groups;
Amendment 89 #
Paragraph 24 b (new)
24 b. Calls on European Commission to lead discussions with Member States on how to best equip primary care professionals (such as inclusion of anti- HCV and HbsAg in health check-ups, anamnesis, follow up tests, referral pathways), with a view to increasing the diagnosis rate and ensuring guideline- conform care;
Amendment 91 #
Paragraph 24 c (new)
24 c. calls on the European Commission and Member States to ensure sustainable funding of National Viral Hepatitis Elimination Plans, also making use of EU Structural Funds and other available EU funding;